Navigation Links
Champions' CFO Resigns
Date:1/14/2011

BALTIMORE, Jan. 14, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced today the resignation of Mark Schonau, Champions' Chief Financial Officer. Mr. Schonau indicated that he has no disagreements with management and has resigned to pursue other opportunities. Champions is seeking chief financial officer candidates and intends to complete the search in the near future.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced translational platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Technology Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnology.com

Contact: Joel Ackerman, CEO, 410 369 0365


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology Awarded $1.46 million in Grants
2. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Paul D. Duke Resigns From Mesas Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 ... report on the global market for intraoperative imaging, ... presently valued at US$ 513.9 million. According to ... keep surging on the grounds of increasing adoption ... the field of diagnostic imaging for neurosurgeries. The ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic Devices ... over the next decade to reach approximately $8.9 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology:
(Date:2/23/2017)... Cranbury, NJ (PRWEB) , ... February 23, 2017 ... ... Cure®, the pre-eminent publication and community for those in the fight against cancer, ... was important in their success. HRA will release top-line findings in a ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing quality ... conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. ... Mason Health System in Seattle since 2000. In addition to his role at Virginia ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing ... sit stand solutions representative to the Minneapolis Home and Garden Show which is being ... that is garnering national attention is the Minneapolis Convention Center. , From its ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
Breaking Medicine News(10 mins):